

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

NCT06619561

Status	RECRUITING
Phase	Phase 2
Sponsor	Deciphera Pharmaceuticals, LLC
Enrollment	48 participants

Key Eligibility Criteria

Inclusion (7)

- Must be allogeneic hematopoietic stem cell transplant (HSCT) recipients with moderate to severe cGVHD requiring systemic immune suppression.
- a. May have persistent active acute GVHD (aGVHD) and chronic GVHD (cGVHD) manifestations (overlap syndrome).
- Participants with active cGVHD who have received and failed at least 2 prior lines of systemic therapy.
- Stable dose of systemic corticosteroids is permitted but not required. If being taken, participants should be on a stable dose of corticosteroids for at least 2 weeks prior to starting study drug treatment.
- Adequate organ and bone marrow functions.

... and 2 more (see full listing online)

Exclusion (7)

- Has aGVHD without manifestations of cGVHD.
- Prior use of colony-stimulating factor 1 receptor (CSF1R) inhibitor for cGVHD.
- History or other evidence of severe illness, uncontrolled infection, or any other conditions that would make the participant unsuitable for the study. All wounds must be healed and free of infection or dehiscence.
- History of malignancy except for:
- Underlying malignancy for which the transplant was performed

... and 2 more (see full listing online)

Locations (26 total)

City of Hope National Medical Center, Duarte, California, United States
Ronald Regan UCLA Medical Center, Los Angeles, California, United States
University of California Irvine Health, Orange, California, United States
... and 23 more locations